John Renger - 13 Apr 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 13 Apr 2022
Net transactions value: -$1,401,592
Form type: 4
Filing time: 15 Apr 2022, 16:19:10 UTC
Previous filing: 31 Mar 2022
Next filing: 07 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$157,500	+45,000	+2273%	$3.50^*	46,980	13 Apr 2022	Direct	F1
transaction	CERE	Common Stock	Sale	$1,559,092	-45,000	-96%	$34.65	1,980	13 Apr 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-45,000	-19%	$0.000000	190,875	13 Apr 2022	Common Stock	45,000	$3.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.28 to $34.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.